Related by context. All words. (Click for frequent words.) 74 vitro studies 70 vivo experiments 69 pharmacokinetic studies 69 preclinical efficacy 69 tumorigenicity 69 immunohistochemical analysis 68 GRNCM1 68 Immunohistochemical analysis 68 ENMD # 67 preclinically 67 flavopiridol 67 NOD SCID mice 67 vivo 66 Preclinical studies 66 OMP #M# 66 vimentin 66 rBChE 66 pharmacodynamic PD 66 syngeneic 65 xenograft models 65 antisense inhibition 65 depsipeptide 65 immunized mice 65 immunohistochemical 65 nonclinical studies 65 NOD mouse 65 #F FDG PET 65 Pharmacokinetic studies 65 transgenic mouse models 65 preclinical studies 65 potent inhibition 65 transgenic rats 65 phylogenetic analyzes 65 mechanistic insights 65 immunological responses 65 Lodamin 65 PPARγ 65 dose proportionality 65 CGEN # 65 delafloxacin 64 XmAb# 64 Symadex 64 pharmacodynamic effects 64 Macaca mulatta 64 ImmunoVEX HSV2 64 riociguat 64 gene amplification 64 BMS# 64 TNFa 64 laboratory experiments 64 biodistribution studies 64 Subgroup analysis 64 MGd 64 DXL# 64 tyrosine phosphorylation 64 fosbretabulin 64 p# activation 64 annexin V 64 murine models 64 potent inhibitors 64 selective inhibition 64 murine model 64 Annexin V 64 chlamydial 64 virulence genes 64 situ hybridization 63 ^ sup #m 63 Pharmacokinetic PK 63 ganetespib 63 antitumor efficacy 63 plasma pharmacokinetics 63 NOD mice 63 Immunohistochemistry 63 cultured cells 63 solithromycin 63 vitro 63 HepG2 cells 63 pDCs 63 fumagillin nanoparticles 63 transfected cells 63 mouse xenograft 63 GLP toxicology studies 63 ultrastructural 63 cynomolgus monkeys 63 CCR9 63 transgene expression 63 K ras mutations 63 CCR2 63 vitro cytotoxicity 63 cMET 63 Thiovir 63 rifamycins 63 toxicological studies 63 XL# inhibits 63 masitinib 63 HCV replication 63 orthotopic 63 cannabinor 63 genotypic 63 E. faecalis 62 antiproliferative effects 62 antiangiogenic activity 62 Phase Ib study 62 selective modulator 62 oxysterols 62 ESBA# 62 CXCR7 62 immunohistochemical staining 62 cediranib 62 immunostaining 62 retapamulin 62 PC# cells 62 subgroup analyzes 62 proteomes 62 iroxanadine 62 trastuzumab Herceptin ® 62 bioluminescence imaging 62 xenografts 62 immunofluorescence staining 62 PSMA ADC 62 mouse xenograft models 62 NITD# 62 novel peptide 62 cisplatin resistant 62 pharmacodynamic markers 62 mTOR inhibition 62 cDNAs 62 db db mice 62 busulfan 62 pharmacodynamic properties 62 proteomic analysis 62 serum antibody 62 DFMO 62 neutralizing antibody 62 mtDNA mutations 62 SGS# 62 radiolabeled TM# 62 small molecule activators 62 transcriptional profiling 62 transcriptional regulation 62 β1 62 favorable pharmacokinetic profile 62 somatostatin 62 Phylogenetic analyzes 62 anti leukemic 62 neuropilin 62 mice lacking 62 enzastaurin 62 proteolytic cleavage 62 isotype 62 histopathologic examination 61 differentially expressed genes 61 Preclinical Study 61 Phase Ib clinical trials 61 microarray analysis 61 bacterial genomes 61 Aplidin 61 HIF PH inhibitors 61 BioVant 61 ALB # 61 bleomycin 61 transgenic mouse model 61 NSCLC tumors 61 milatuzumab 61 Liver biopsies 61 immunoblotting 61 APOPTONE 61 receptor inhibitor 61 bioluminescent imaging 61 vivo efficacy 61 imetelstat 61 murine 61 edifoligide 61 MPTP 61 WT1 61 adenoviral 61 anticancer activity 61 Cytochrome P# 61 GRN# 61 neuronal differentiation 61 potent antitumor activity 61 PlGF 61 biochemical abnormalities 61 IL #E 61 RT qPCR 61 mTOR inhibitors 61 humanized mouse 61 MET amplification 61 quantitative RT PCR 61 anti fibrotic 61 PEG SN# 61 triphendiol 61 LB# [003] 61 GAP #B# 61 nanoviricides 61 Confocal microscopy 61 antisense inhibitors 61 CaPre TM 61 viral kinetics 61 genotypic resistance 61 C. pneumoniae 61 inhibitory effects 61 peripheral blood mononuclear 61 peptide antigens 61 PXD# 61 histopathological examination 61 Phase Ib clinical 61 IgG1 antibodies 61 splice variants 61 TACI Ig 61 Phase 1b clinical trials 61 TLE3 61 OXi# 61 ALDH br cells 61 follicular fluid 61 PARP inhibition 61 biodistribution 61 remyelination 61 forskolin 61 prognostic significance 61 Homspera 61 demonstrated antitumor activity 61 Multivariate analysis 61 biopsied tissue 61 beta1 integrin 61 orally dosed 61 RAV# 61 paricalcitol 61 immunoreactivity 61 genetically altered mouse 61 histone deacetylase inhibitor 61 vivo validation 61 activin 61 microglial 61 experimentally induced 61 physiologically relevant 61 GAMMAGARD 61 systemically administered 61 xenograft 61 alagebrium 61 amino acid substitutions 61 antitumor effects 61 gene inactivation 61 CXCR4 61 olaparib 61 HCV SPRINT 61 MAPCs 61 AST ALT 61 hMG 61 highly immunogenic 61 histopathologic diagnosis 61 neurotrophic 61 trodusquemine 61 antiangiogenic 61 Valortim R 61 Six3 60 Multiple logistic regression 60 Trofex 60 Lp PLA 2 60 MenSCs 60 redox active 60 CALGB 60 vidofludimus 60 hypermethylation 60 potently inhibited 60 lenalidomide dexamethasone 60 CG# [003] 60 vitro assay 60 c MYC 60 Nonclinical 60 vivo preclinical 60 radioimmunoassay 60 INGAP 60 bronchial epithelial cells 60 gene polymorphisms 60 promoter methylation 60 HGS ETR1 60 FTIs 60 lymphocyte counts 60 PTHrP 60 Estrogen Receptor 60 cultured neurons 60 PBMCs 60 #ß 60 orally bioavailable 60 SIRT1 activation 60 IFN β 60 microarray experiments 60 plasma kallikrein 60 transfected 60 mecamylamine 60 intravenous dosing 60 PD LID 60 intracellular bacteria 60 tumor specific antigen 60 mechanistic studies 60 CRLX# 60 NAbs 60 multicenter clinical trials 60 Angiolix 60 Anticalins ® 60 anti Neu5Gc antibodies 60 LT NS# 60 Immunohistochemical 60 OHR/AVR# 60 FUS1 60 genetic polymorphisms 60 metabolomic profiling 60 liposomal amphotericin B 60 chromosomal aberrations 60 mutational analysis 60 adipose derived stem cells 60 partial agonists 60 S/GSK# 60 neuroimaging studies 60 S. maltophilia 60 uPAR 60 carcinoembryonic antigen 60 EGF receptor 60 bazedoxifene conjugated estrogens 60 GRNVAC1 60 replicon 60 TRIOLEX 60 mutant SOD1 60 MTT assay 60 F FDG PET 60 CBLC# 60 OvaRex MAb 60 B7 H3 60 thymosin 60 coexpression 60 preclinical pharmacokinetic 60 biochemical assays 60 siRNA knockdown 60 GPx 60 CA4P 60 Panzem 60 methylation markers 60 tumor regressions 60 pharmacokinetic PK study 60 AEG# 60 Immunohistochemical staining 60 Smoothened 60 antiangiogenesis 60 intracoronary 60 annexin 60 demyelinating 60 Multimeric 60 florbetaben 60 T#I [002] 60 huC# DM4 60 P selectin 60 oral prodrug 60 mediated inhibition 60 HLA alleles 60 #F FDG 60 LY# [002] 60 phylogenetic analysis 60 PROCHYMAL 60 methylation patterns 60 lymphoid cells 60 Histological examination 60 DNA demethylation 60 EDEMA3 trial 60 bortezomib Velcade 60 RRM1 60 TIMP 1 60 pegylated liposomal doxorubicin 60 vivo preclinical studies 60 pharmacokinetic PK 60 Xelox 60 Dr. Gambotto 60 FLT3 60 Safinamide 60 HuMax CD# 60 Meta analyzes 60 cardioprotective effects 60 inhibitor RG# 60 HCV replicon 60 basal bolus regimen 60 DermaVir 60 Cyclin E 60 VA# [002] 60 LRP6 60 synovial tissue 60 oxidized lipids 60 Cathepsin B 60 HuMax EGFr 60 Phylogenetic analysis 60 Prof. Gozes 60 JAK2 60 CD#c 60 pharmacokinetic interactions 60 Onconase 60 bovine thrombin 60 deacetylation 60 Kahalalide F 60 explants 60 BEZ# 60 elastase 60 molecular biomarkers 60 DNA hypermethylation 60 colorectal adenocarcinoma 60 pharmacokinetic characteristics 60 Sym# 60 indibulin 60 mRNA expression 60 antidepressant efficacy 60 miR #a [001] 60 potent anti angiogenic 60 histopathological 60 fluvastatin 60 gamma secretase inhibitor 60 GFT# 60 antitumour activity 60 MEK inhibitor 60 plasma kallikrein inhibitor 60 BMP2 60 herpesviruses 60 miRNA expression 60 urocortin 2 60 VEGFb 60 alveolar epithelial cells 60 interferon IFN 60 alpha7 60 IGFBP2 60 inosine 60 somatic mutations 60 subcellular localization 60 E#F# 60 interleukin IL -# 60 IDH1 mutation 60 hematopoietic progenitor cells 60 immunoglobulin G 59 Sprague Dawley rats 59 neratinib 59 pan HDAC inhibitor 59 sequence homology 59 PCR assay 59 CCX# 59 histone deacetylase inhibitors 59 potently inhibit 59 oral JAK1 59 CDK inhibitor 59 homodimers 59 heterologous expression 59 vivo assays 59 isotypes 59 liposomal doxorubicin 59 Subgroup analyzes 59 QTc prolongation 59 HEK# cells 59 prostate carcinoma 59 prostanoid 59 FGFs 59 gene loci 59 serotonin synthesis 59 organogenesis 59 enkephalin 59 constitutively active 59 Clusterin 59 ERK1 2 59 Multivariate logistic regression 59 antitumor effect 59 CD# expression [001] 59 transcriptomic 59 Flt3 59 CTAP# Capsules 59 mammary cells 59 uricase 59 soluble receptor 59 chimeric mouse 59 ADAGIO study 59 eotaxin 59 outer membrane proteins 59 benfotiamine 59 downregulation 59 DNA methylation markers 59 V#F mutation 59 chromatin immunoprecipitation 59 cyclophilin D 59 endostatin 59 Factor VIIa 59 JAK inhibitor 59 Inosine 59 Prox1 59 endotoxemia 59 alvespimycin 59 RT PCR assay 59 gene rearrangements 59 tumor biopsies 59 molecular determinants 59 N. gonorrhoeae 59 serum antibodies 59 MMP# 59 PKM2 59 K ras 59 Posiphen 59 GRP# 59 p# MAPK 59 Lpathomab 59 Radilex 59 Western blotting 59 myo inositol 59 telomerase gene 59 pharmacodynamic profile 59 pharmacokinetic parameters 59 CagA 59 LC#m# 59 ELISPOT 59 LSI #P 59 NOX E# 59 paralogs 59 PPARgamma 59 fumagillin 59 #F FDG PET CT 59 midstage trials 59 experimental autoimmune encephalomyelitis 59 caspofungin 59 M1 muscarinic 59 dexamethasone Decadron 59 ELISpot 59 Wnts 59 GLYX 59 ADAMTS# 59 REP# 59 fluorescently tagged 59 iPSC 59 Slukvin 59 malignant transformation 59 KB# [002] 59 culture supernatants 59 constitutively expressed 59 Genotypes 59 Rab5 59 osteoblast 59 apolipoproteins 59 PrPSc 59 P. gingivalis 59 CR# vcMMAE 59 hERG 59 hyperinsulinemic euglycemic clamp 59 randomized multicenter trial 59 supernatants 59 antigenic epitopes 59 TGF ß 59 parthenolide 59 CORT # 59 chemopreventive agent 59 PML RARA 59 pharmacodynamic parameters 59 Microscopic examination 59 microRNA expression 59 pomalidomide 59 haematopoietic 59 radiolabeled 59 mGluR2 NAM 59 Dr. Pasinetti 59 mertansine 59 posttranslational modification 59 CEACAM1 59 hepatoma 59 Pharmacokinetic 59 JAK2 inhibitor 59 bioassay 59 beta interferons 59 hA# 59 genomewide association study 59 ERK signaling 59 small molecule agonists 59 GSK # 59 CXCR2 59 immunodeficient mice 59 phosphate S1P 59 ocular formulation 59 adenovirus vectors 59 antiangiogenic agents 59 multivariate analyzes 59 EUS FNA 59 hTERT 59 Tie2 59 FGFR4 59 multicenter Phase II 59 Leydig cells 59 pharmacodynamic endpoints 59 Zybrestat 59 BRAF mutation 59 IGFBP 3 59 PI3K inhibitor 59 preclinical 59 HBx 59 HuR 59 mycobacterial 59 microRNA miR 59 Xanafide 59 safety tolerability pharmacokinetic 59 MAGE A3 ASCI 59 metastatic neuroendocrine tumors 59 bispecific antibody 59 favorable pharmacokinetic 59 AQ4N 59 antitumor 59 proto oncogene 59 gamma tocotrienol 59 Interferon Beta 59 methylated DNA 59 qRT PCR 59 antiviral potency 59 INGN 59 FK# 59 HER2 overexpression 59 RGB # 59 Sphingomab 59 transgenic mice 59 Cervista HPV HR 59 mutant strains 59 Tß4 59 IgG1 59 ovariectomized 59 SIRT2 59 Hedgehog inhibitor 59 epigenetic mechanisms 59 mg kg dose 59 FDG-PET/CT 59 pharmacokinetic equivalence 59 Hepatotoxicity 59 sitaxsentan 59 histological examination 59 histone modifications 59 monomeric 59 PIK3CA 59 IGF IR 59 HDAC inhibitors 59 PRT# 59 nonhuman primates 59 lysate 59 seliciclib 59 IFN gamma 59 human microdosing 59 fluoroquinolone resistance 59 apoE 58 TNF α 58 melatonin receptor 58 anti CD3 antibody 58 prion infection 58 PDGFR 58 S#A# [002] 58 RE LY trial 58 MVA BN R 58 Epidemiologic studies 58 urease 58 Phase 1b trial 58 CYT# potent vascular disrupting 58 nucleotide substitutions 58 cilengitide 58 Vacc 4x 58 NS#/#A protease 58 TLR8 58 xenograft tumors 58 STAT3 signaling 58 protein electrophoresis 58 PLX cells 58 immunotoxins 58 RQ PCR 58 antiangiogenic agent 58 pro angiogenic 58 TTR gene 58 splenocytes 58 IgM antibody 58 oral bioavailability 58 prostate epithelial cells 58 GHRH 58 dose dependently 58 colon carcinoma 58 glucocorticoid receptor 58 hippocampal neurons 58 urocortin 58 nAChR 58 vitro assays 58 ZFN modified 58 Microarray analysis 58 BNC# 58 teriflunomide 58 potent stimulator 58 NEUGENE 58 Gleevec resistant 58 R roscovitine 58 tumor regression 58 BMP4 58 mammographic density 58 antiviral efficacy 58 mdx mouse 58 antisense inhibitor 58 Phase IIb clinical trials 58 ATL# [001] 58 hematopoietic cells 58 #S rRNA gene 58 flow cytometric analysis 58 NGAL 58 proteasome inhibitor 58 anti proliferative 58 elacytarabine 58 chimerism 58 VAPRISOL 58 viral genomes 58 VADT 58 Leydig cell 58 lysophosphatidic acid 58 tolerability profiles 58 JAK inhibitors 58 ribonuclease 58 CDK4 58 axitinib 58 sarcosine 58 #I TM# 58 clinical pharmacology studies 58 ABL1 58 prion infected 58 cells overexpressing 58 Seliciclib 58 bronchoalveolar lavage 58 ABCB1 58 gastrin 58 missense mutations 58 neuroprotective effects 58 silico prediction 58 mitochondrial DNA mtDNA 58 radezolid 58 AMD# [003] 58 hepatic fibrosis 58 ritonavir boosted 58 ectopic expression 58 clusterin 58 IFN beta 58 mimetics 58 antagomirs 58 huN# DM1 58 differential gene expression 58 varespladib 58 mapatumumab 58 Phase 1a clinical 58 lentiviral 58 decitabine 58 immune modulating 58 pleiotrophin 58 genomic profiling 58 airway hyperresponsiveness 58 Fc fusion protein 58 LHRH receptor positive 58 proteomic analyzes 58 ChR2 58 IL 1β 58 statistically significant correlations 58 genetic polymorphism 58 Ampligen ® 58 LPS induced 58 antitumoral 58 TRAIL induced apoptosis 58 davunetide intranasal AL 58 INCB# [003] 58 multiple logistic regression 58 nelfinavir 58 DAVANAT 58 galiximab 58 CCR7 58 CPEB 58 immunofluorescence microscopy 58 metabolite concentrations 58 immunotoxin 58 FGFR2 58 miR #a [002] 58 genotoxicity 58 APTIVUS r 58 orthologs 58 Bortezomib 58 IL 1ß 58 Akt activation 58 phase Ib 58 cellular prion protein 58 adipocyte differentiation 58 MVA MUC1 IL2 58 potent neuroprotective 58 Logistic regression 58 VEGF inhibitors 58 multivariate logistic regression 58 chemokine receptor 58 #beta HSD1 58 microarray gene expression 58 radiotracers 58 kinase inhibition 58 liver biopsies 58 immunomodulatory therapy 58 heparan sulfate 58 Blinatumomab 58 EGFR HER2 58 JAK2 inhibitors 58 potentiation 58 phase IIb study 58 Belerofon 58 placebo controlled clinical trials 58 amyloid deposition 58 elotuzumab 58 assay detects 58 immunoblot 58 preclinical toxicology 58 dose escalation Phase 58 PCK# 58 eTag assays 58 ON #.Na 58 RNA polymerases 58 ChIP chip 58 inecalcitol 58 FSH receptor 58 defensin 58 Azedra 58 Carfilzomib 58 infantile NCL 58 polyclonal 58 protein kinase inhibitor 58 CYP#D# 58 HDACi 58 BRAF inhibitor 58 Alkaline Phosphatase 58 MUC1 58 SERMs 58 antiangiogenic therapy 58 PDE4 inhibitor 58 alkylating agent 58 cathepsins 58 S. neurona 58 pharmacokinetic 58 P#X# 58 vitro maturation 58 rHuEPO 58 brivaracetam 58 radiation dosimetry 58 phase IIa 58 epithelial tumors 58 bactericidal activity 58 microglial activation 58 TNFalpha 58 PC3 cells 58 neuroblastoma cells 58 FKBP# 58 mutant proteins 58 K RAS 58 anti CD3 58 ependymomas 58 cell lysate 58 retaspimycin 58 cell lysis 58 trastuzumab Herceptin R 58 hESC derived cardiomyocytes 58 miR #b [001] 58 pharmacokinetics PK 58 metabolomic profiles 58 MAPK pathway 58 non nucleoside 58 clonogenic 58 micafungin 58 mRNA transcripts 58 microdose 58 Triolex 58 Foxp3 58 liposome formulation 58 previously uncharacterized 58 SIV infected 58 thioredoxin 58 FGF2 58 induced sputum 58 pharmacodynamic profiles 58 ANAVEX #-# [001] 58 dexpramipexole 58 receptor antagonism 58 gene expression microarray 58 microdialysis 58 oncomodulin 58 Wnt signaling pathway 58 PEG IFN 58 bcl 2 58 bile acid metabolism 58 dedifferentiation 58 RNA seq 58 DNMT1 58 trophoblast cells 58 quasispecies 58 Genotypic 58 urine cytology 58 BMP signaling 58 HIF 1α 58 miRs 58 SAR# [004] 58 PEGPH# 58 C#BL 6 mice 58 protein encoded 58 ConclusionThis 58 airway responsiveness 58 NEUGENE antisense 58 virologic responses 58 site directed mutagenesis 58 Wwox 58 interferon gamma 58 mesothelin 58 placebo controlled studies 58 tumoral 58 glioblastoma cells 58 MDR1 58 Histopathologic examination 58 HGS ETR2 58 mutant mouse 58 synthetic peptides 58 array CGH 58 synthetic peptide 58 Jurkat cells 58 Phase #b/#a trial 58 morphogen 58 intravesical instillation 58 transgenic mouse 58 Guanilib 58 fibrotic disease 58 CB2 receptor 58 eosinophil count 58 HIF 1a 58 Immunohistochemistry IHC 58 Ocrelizumab 58 ATL# [002] 58 Squalamine 58 Dr. Sosne 58 GABAergic interneurons 58 oncolytic virus 58 immunomodulation 58 EOquin TM 58 zebrafish embryos 58 RNAi mediated 58 secretin 58 GSTP1 58 IL 1beta 58 replicase 58 IMA# 58 ovarian carcinoma 58 embryonal carcinoma 58 HER2/neu 58 Vpu 58 CDK inhibitors 58 Plain radiographs 58 prion strains 58 chest radiographs 58 MMP inhibitors 58 GSOs 57 Aflibercept 57 hedgehog pathway 57 heparanase 57 RGD peptides 57 Teriflunomide 57 electrophysiologic 57 PTPN# 57 neutralizing antibody responses 57 steroid dexamethasone 57 MetAP2 57 lung fibroblasts 57 Hcrt 57 Neuropeptide Y 57 APTIVUS 57 inhibiting telomerase 57 pathophysiological effects 57 preclinical models 57 oligonucleotide microarrays 57 antisense compounds 57 tremelimumab 57 MR spectroscopy 57 antiandrogens 57 COX enzymes 57 follistatin 57 FDG PET imaging 57 intratumoral injection 57 PDE#A 57 placebo controlled clinical 57 C1q 57 ZFN modified cells 57 osteoclast 57 midstage clinical trials 57 mammalian fatty acid 57 TPMT 57 Eg5 57 Sipuleucel T 57 Tyrima 57 chemopreventive 57 antitumor activity 57 Prodarsan ® 57 CCR1 57 cytotoxic effects 57 Th2 cytokines 57 FDG PET 57 dosage regimens 57 MMP inhibitor 57 cathepsin B 57 Univariate analysis 57 massively parallel sequencing 57 YONDELIS